Analysts await Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-0.29 EPS, down 3.45% or $0.01 from last year’s $-0.28 per share.

At the moment 4 analysts are watching Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), 2 rate it “Buy”, 2 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 2 analysts have a mean sales target of 0.00 million. For the quarter ending Sep-16, 2 analysts have a mean sales target of 0.00 million whilst for the year ending Dec-16, 5 analysts have a mean target of 2.00 million.

In terms of earnings per share, 4 analysts have a -0.31 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 4 analysts have a -0.35 EPS mean target and for the quarter ending Sep-16 there are 6 estimates of -1.55 EPS.

The biggest institutional shareholders in Anthera Pharmaceuticals, Inc. include Zenyaku Kogyo Co Ltd which owns 3 million shares in the company valued at $13.67 million. Franklin Advisers, Inc. is the second biggest holder with 3 million shares currently valued at 12.61 million whilst Fidelity Management and Research Company has 3 million shares valued at 12.00 million.

Total shares held by institutions as of the most recent company filings are 25,229,243 with a reported 2,290,804 bought and 2,233,120 sold. These holdings make up 63.44% of the company’s outstanding shares.

Currently insiders hold 773,234 shares in the business which makes up 1.93% of shares. The biggest holder currently is Dr. Christopher S. Henney, PhD who owns 202,429 shares (0.51% of those outstanding), whilst Dr. Joaquim Trias,PhD holds 198,546 (0.50% of shares outstanding) and Christopher P. Lowe holds 108,915 (0.27% of shares outstanding).

The stock decreased 3.21% or $0.1 during the last trading session, hitting $4.00. Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) has fallen 46.75% over the past 6 months and is downtrending.